Physician profile
Joy Boyne
NPI 1386757540
$667.37
in general payments reported to CMS, 2019-2025
12 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $24.41 · 2021: $11.82 · 2022: $26.52 · 2023: $28.19 · 2024: $195 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.67 | 2024-2025 | |
| Genzyme Corporation | $147.42 | 2019-2024 | |
| Abbvie INC. | $66.30 | 2019-2025 | |
| Lilly USA, LLC | $59.62 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $36.23 | 2020-2021 | |
| Almirall LLC | $32.99 | 2025 | Klisyri |
| Galderma Laboratories, L.P. | $29.07 | 2024-2025 | Aklief |
| Journey Medical Corporation | $26.52 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.21 | 2025 | Dupixent |
| Hill Dermaceuticals, INC. | $23.94 | 2024 | Tolak |
| Arcutis Biotherapeutics, INC. | $21.20 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $20.20 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Boyne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.